Scholarlink

<p>Rituximab has never been investigated in MRD persistence/relapse. We describe a clinical picture of a woman with Ph-negative B-ALL CD20<sup>+</sup>, ineligible to allogeneic transplant, achieving MRD eradication using rituximab monotherapy after frontline chemotherapy and blinatumomab failure. This demonstrates rituximab’s potential in MRD<sup>+</sup> Ph-negative B-ALL CD20<sup>+</sup>, warranting further clinical investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20+

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月16日

查看全文
  • Nicola Cecchi,
  • Mariarita Sciumè,
  • Antony Ricchiuti,
  • Alessandro Bosi,
  • Elena Tagliaferri,
  • Francesco Passamonti,
  • Nicola Stefano Fracchiolla

摘要

Rituximab has never been investigated in MRD persistence/relapse. We describe a clinical picture of a woman with Ph-negative B-ALL CD20+, ineligible to allogeneic transplant, achieving MRD eradication using rituximab monotherapy after frontline chemotherapy and blinatumomab failure. This demonstrates rituximab’s potential in MRD+ Ph-negative B-ALL CD20+, warranting further clinical investigation.